Key facts
- Soufflé Therapeutics’s last known valuation is $344.5M (Oct 2025).
- It has raised $240.6M across 1 recorded rounds; the latest was Early Stage VC (Series A) ($200.0M) in Oct 2025.
- Notable investors include Bessemer Venture Partners, Temasek Holdings, Breyer Capital, ARCH Venture Partners, Safar Partners — 13 tracked in total.
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Soufflé Therapeutics
Funding rounds
1 roundsAbout Soufflé Therapeutics
Developer of a targeted gene therapy intended to treat autoimmune diseases and cardiac diseases. The company develops a platform for targeted, tissue-specific genetic therapy delivery through the discovery of new cell proteins and pathways that can deliver genetic payloads, enabling healthcare professionals to target macrophages and cardiac cells for the treatment of autoimmune diseases and cardiac diseases.
- Industry
- Therapeutic Devices
- Sector
- Healthcare
- HQ
- Watertown, MA, United States
- Founded
- 2021
- Employees
- 65
- Website
- souffletx.com/
- Ownership
- Privately Held (backing)
Soufflé Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Soufflé Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Soufflé Therapeutics in its N-PORT filings yet. We sweep new filings monthly.